論文 - アレクシッチ　ブランコ

Genetic evidence for association between <i>NOTCH4</i> and schizophrenia supported by a GWAS follow-up study in a Japanese population 査読有り

Ikeda, M; Aleksic, B; Yamada, K; Iwayama-Shigeno, Y; Matsuo, K; Numata, S; Watanabe, Y; Ohnuma, T; Kaneko, T; Fukuo, Y; Okochi, T; Toyota, T; Hattori, E; Shimodera, S; Itakura, M; Nunokawa, A; Shibata, N; Tanaka, H; Yoneda, H; Arai, H; Someya, T; Ohmori, T; Yoshikawa, T; Ozaki, N; Iwata, N

MOLECULAR PSYCHIATRY   18 巻 ( 6 ) 頁： 636 - 638   2013年6月

　詳細を見る

記述言語：英語   出版者・発行元：Molecular Psychiatry  

DOI： 10.1038/mp.2012.74

Web of Science

Scopus

PubMed

researchmap

その他リンク： http://orcid.org/0000-0003-1761-6314

Analysis of the <i>VAV3</i> as Candidate Gene for Schizophrenia: Evidences From Voxel-Based Morphometry and Mutation Screening 査読有り 国際誌

Aleksic, B; Kushima, I; Hashimoto, R; Ohi, K; Ikeda, M; Yoshimi, A; Nakamura, Y; Ito, Y; Okochi, T; Fukuo, Y; Yasuda, Y; Fukumoto, M; Yamamori, H; Ujike, H; Suzuki, M; Inada, T; Takeda, M; Kaibuchi, K; Iwata, N; Ozaki, N

SCHIZOPHRENIA BULLETIN   39 巻 ( 3 ) 頁： 720 - 728   2013年5月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Schizophrenia Bulletin  

In recently completed Japanese genome-wide association studies (GWAS) of schizophrenia (JPN-GWAS) one of the top association signals was detected in the region of VAV3, a gene that maps to the chromosome 1p13.3. In order to complement JPN-GWAS findings, we tested the association of rs1410403 with brain structure in healthy individuals and schizophrenic patients and performed exon resequencing of VAV3. We performed voxel-based morphometry (VBM) and mutation screening of VAV3. Four independent samples were used in the present study: (1) for VBM analysis, we used case-control sample comprising 100 patients with schizophrenia and 264 healthy controls, (2) mutation analysis was performed on a total of 321 patients suffering from schizophrenia, and 2 case-control samples (3) 729 unrelated patients with schizophrenia and 564 healthy comparison subjects, and (4) sample comprising 1511 cases and 1517 healthy comparison subjects and were used for genetic association analysis of novel coding variants with schizophrenia. The VBM analysis suggests that rs1410403 might affect the volume of the left superior and middle temporal gyri (P =. 011 and P =. 013, respectively), which were reduced in patients with schizophrenia compared with healthy subjects. Moreover, 4 rare novel missense variants were detected. The mutations were followed-up in large independent sample, and one of the novel variants (Glu741Gly) was associated with schizophrenia (P =. 02). These findings demonstrate that VAV3 can be seen as novel candidate gene for schizophrenia in which both rare and common variants may be related to increased genetic risk for schizophrenia in Japanese population. © 2012 The Author.

DOI： 10.1093/schbul/sbs038

Web of Science

Scopus

PubMed

researchmap

Effects of repeated dosing with mirtazapine, trazodone, or placebo on driving performance and cognitive function in healthy volunteers

Sasada, K; Iwamoto, K; Kawano, N; Kohmura, K; Yamamoto, M; Aleksic, B; Ebe, K; Noda, Y; Ozaki, N

HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL   28 巻 ( 3 ) 頁： 281 - 286   2013年5月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

<jats:sec><jats:title>Objective</jats:title><jats:p>This study aimed to evaluate the effects of repeated treatments with the sedative antidepressants mirtazapine and trazodone on driving performance and cognitive function.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Nineteen healthy men received continuous nocturnal doses of 15‐mg mirtazapine , 25‐mg trazodone, or placebo for 8 days in a double‐blinded, three‐way crossover trial. Subjects were asked to perform three driving tasks (road tracking, car following, and harsh braking) using a driving simulator and cognitive tasks (the Wisconsin Card Sorting Test, Continuous Performance Test, and N‐back Test) at baseline and on Days 2 and 9. Stanford Sleepiness Scale scores were also assessed.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Mirtazapine significantly increased the standard deviation of lateral position in the road‐tracking task as compared with trazodone on Day 2. Mirtazapine significantly increased Stanford Sleepiness Scale scores as compared with trazodone and placebo. For the remaining tasks, no significant effects of treatment were observed.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Acute treatment of mirtazapine impaired road‐tracking performance and increased sleepiness, but sedative effects disappeared under repeated administrations. Trazodone did not affect driving performance or cognitive function under acute or repeated administrations. Both initial sedative effects and pharmacological profiles should be taken into consideration when using sedative antidepressants. Copyright © 2013 John Wiley & Sons, Ltd.</jats:p></jats:sec>

DOI： 10.1002/hup.2321

Web of Science

Scopus

PubMed

CiNii Research

researchmap

Total palliative care for a patient with multiple cerebral infarctions that occurred repeatedly in association with gastric cancer (Trousseau's syndrome) 査読有り 国際誌

Ukai, K; Okajima, A; Yamauchi, A; Sasaki, E; Yamaguchi, Y; Kimura, H; Aleksic, B; Ozaki, N

PALLIATIVE & SUPPORTIVE CARE   11 巻 ( 2 ) 頁： 169 - 172   2013年4月

　詳細を見る

記述言語：英語   出版者・発行元：Palliative and Supportive Care  

Objective: Malignancy-related thromboembolism, also referred to as Trousseau's syndrome, can present as acute cerebral infarction, nonbacterial thrombotic endocarditis (NBTE), and migratory thrombophlebitis. Therefore, many physical, neurological, and psychological symptoms associated with Trousseau's syndrome may occur in the clinical course. Method: To illustrate this, we report a case of a male patient in his 50s with carcinomatous peritonitis caused by gastric cancer, with multiple cerebral infractions that developed during disease progression. The patient was admitted to our hospital for the treatment of side effects of chemotherapy, although he strongly hoped to go home as soon as possible. In addition to making social supports plans, we were required to perform intensive total palliative care, because of his physical pain, general fatigue, anorexia, abdominal and neck pain, and psychological issues (insomnia, delirium, depression, suicidal thoughts, self-mutilation, panic attacks, agoraphobia, fear of death, and feelings of hopelessness). Results: To the best of our knowledge, based on the literature search, this is the first reported case of Trousseau's syndrome described in the context of total palliative care, especially psychological care. Significance of results: We propose that neurological symptoms of Trousseau's syndrome cause these extensive mental disorders. Furthermore, because of the prognosis of Trousseau's syndrome, we should utilize our expertise fulfill the patient's wishes. © 2012 Cambridge University Press.

DOI： 10.1017/S1478951512000624

Web of Science

Scopus

PubMed

researchmap

Effects of sedative antidepressants on prefrontal cortex activity during verbal fluency task in healthy subjects: a near-infrared spectroscopy study 査読有り

Kohmura, K; Iwamoto, K; Aleksic, B; Sasada, K; Kawano, N; Katayama, H; Noda, Y; Noda, A; Iidaka, T; Ozaki, N

PSYCHOPHARMACOLOGY   226 巻 ( 1 ) 頁： 75 - 81   2013年3月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Psychopharmacology  

Rationale: Japanese researchers have recently conducted studies using near-infrared spectroscopy (NIRS) to help diagnose psychiatric disorders based on changes in brain activity. However, the influence of psychotropic drugs on NIRS measurements has not been clarified. Objective: To assess the effects of sedative antidepressants on prefrontal cortex activity in healthy subjects using NIRS in a double-blinded, placebo-controlled, crossover trial. Methods: Nineteen healthy males received nocturnal doses of mirtazapine 15 mg, trazodone 25 mg, or placebo for eight consecutive days in rotation, with a washout period of more than 1 week between each rotation. Subjects performed a verbal fluency task during NIRS on a total of seven occasions during the study period: more than a week prior to receiving the first dose of the first medication; and on days 2 and 9 of each rotation. The number of words correctly generated during the task (behavioral performance) was also recorded. Stanford Sleepiness Scale (SSS) scores were determined each day. Results: Mirtazapine 15 mg significantly increased oxyhemoglobin (oxy-Hb) concentration change in NIRS on day 9, compared to trazodone 25 mg and placebo. Mirtazapine 15 mg significantly increased SSS on day 2, compared to the other conditions. No significant differences in behavioral performance were observed. Conclusions: Administration of mirtazapine for eight consecutive days affected oxy-Hb changes on NIRS. This result indicates that researchers should consider how certain types of antidepressant could influence brain function when the brain activity of patients with psychiatric disorders is assessed. © 2012 Springer-Verlag Berlin Heidelberg.

DOI： 10.1007/s00213-012-2885-8

Web of Science

Scopus

PubMed

researchmap

The Postpartum Depressive State in Relation to Perceived Rearing: A Prospective Cohort Study 査読有り

Hayakawa, N; Koide, T; Okada, T; Murase, S; Aleksic, B; Furumura, K; Shiino, T; Nakamura, Y; Tamaji, A; Ishikawa, N; Ohoka, H; Usui, H; Banno, N; Morita, T; Goto, S; Kanai, A; Masuda, T; Ozaki, N

PLOS ONE   7 巻 ( 11 ) 頁： e50220   2012年11月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：PLoS ONE  

Background: The relationship between perceived rearing and the postpartum depressive state remains unclear. We aimed to examine whether perceived rearing is a risk factor for postpartum depression as measured by the Edinburgh Postnatal Depression Scale (EPDS), and whether the score of perceived rearing is affected by depressive mood (the state dependency of perceived rearing). Methods: Pregnant women (n = 448, mean age 31.8±4.2 years) completed the EPDS as a measure of depressive state in early pregnancy (T1), late pregnancy (around 36 weeks), and at 1 month postpartum (T2), and the Parental Bonding Instrument (PBI) at T1 as a measure of perceived rearing. Changes in the EPDS and the PBI scores from T1 to T2 were compared between the non depressive (ND) group and the postpartum depressive (PD) group. Results: There were no significant differences in any PBI category for perceived rearing between the ND and PD groups at T1. EPDS scores did not change significantly from T1 to T2 in the ND group but increased significantly in the PD group. The PBI maternal care score increased significantly in the ND group (p<0.01), while decreasing in the PD group (p<0.05). Additionally, in both the ND and PD groups, significant negative correlation was observed regarding change in the EPDS and PBI maternal care scores from T1 to T2 (r = -0.28, p = 0.013). Conclusions: The present study suggests that perceived rearing is not a strong risk factor for postpartum depression as measured by the EPDS. Furthermore, the results indicated the state dependency of the PBI maternal care score. © 2012 Hayakawa et al.

DOI： 10.1371/journal.pone.0050220

Web of Science

Scopus

PubMed

researchmap

Effectiveness of Duloxetine for the Treatment of Chronic Nonorganic Orofacial Pain 査読有り

Nagashima, W; Kimura, H; Ito, M; Tokura, T; Arao, M; Aleksic, B; Yoshida, K; Kurita, K; Ozaki, N

CLINICAL NEUROPHARMACOLOGY   35 巻 ( 6 ) 頁： 273 - 277   2012年11月

　詳細を見る

記述言語：英語   出版者・発行元：Clinical Neuropharmacology  

OBJECTIVE: We examined the pain-relieving effect of duloxetine on chronic nonorganic orofacial pain (burning mouth syndrome and atypical odontalgia), considering the influence of baseline depressive symptoms. METHODS: In this study of 12 weeks, duloxetine was administered in a fixed-flexible dose of 20 to 40 mg/d to 41 patients with burning mouth syndrome and/or atypical odontalgia. Pain was evaluated using the visual analog scale (VAS) at baseline and at 2, 4, 6, 8, 10, and 12 weeks of treatment. Depressive symptoms were assessed using the Hamilton Depression Rating Scale at baseline and at 12 weeks of treatment. RESULTS: We analyzed the data from 29 patients who completed the study. The VAS score at 12 weeks of treatment was significantly lower than that at baseline. The time course of the VAS scores revealed its significant decrease from 2 weeks of treatment compared to the baseline score. To investigate the influence of baseline depressive symptoms on the pain-relieving effect of duloxetine, the subjects were divided into 2 groups based on the Hamilton Depression Rating Scale score on initial consultation: groups with (≥8) and without (≤7) depressive symptoms. Two-way repeated-measures analysis of variance revealed no significant interaction between time and initial presence or absence of depression. An additional intent-to-treat last-observation-carried-forward analysis including dropped-out patients revealed a similar result. CONCLUSION: Duloxetine significantly relieved chronic nonorganic orofacial pain. Its pain-relieving effect appeared from 2 weeks of treatment. Furthermore, the pain-relieving effects of duloxetine similarly appeared regardless of the presence or absence of baseline depressive symptoms. Copyright © 2012 by Lippincott Williams & Wilkins.

DOI： 10.1097/WNF.0b013e31827453fa

Web of Science

Scopus

PubMed

researchmap

An evaluation of polymorphisms in casein kinase 1 delta and epsilon genes in major psychiatric disorders 査読有り

Matsunaga, S; Ikeda, M; Kishi, T; Fukuo, Y; Aleksic, B; Yoshimura, R; Okochi, T; Yamanouchi, Y; Kinoshita, Y; Kawashima, K; Umene-Nakano, W; Inada, T; Kunugi, H; Kato, T; Yoshikawa, T; Ujike, H; Nakamura, J; Ozaki, N; Kitajima, T; Iwata, N

NEUROSCIENCE LETTERS   529 巻 ( 1 ) 頁： 66 - 69   2012年10月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Neuroscience Letters  

Disturbances of the circadian rhythm are involved in the pathophysiology of bipolar disorder (BD), schizophrenia (SCZ) and major depressive disorder (MDD). Specifically, because clock gene dysfunction is good candidate for enhancing the susceptibility to these psychiatric disorders, we selected two circadian rhythm-related genes (CSNK1D and CSNK1E) and investigated genetic associations of the genes with these three disorders. None of the SNPs showed a significant association with MDD, but a SNP (rs2075984) in CSNK1E and SNP (rs6502097) in CSNK1D were associated with SCZ (P= 0.0091, uncorrected) and BD (P= 0.030, uncorrected), respectively. To confirm these findings, we analyzed an independent dataset (maximum N= 3815) but found a lack of association (P= 0.63 for rs2075984 and P= 0.61 for rs6502097). The final meta-analysis showed no association between these SNPs with SCZ (P= 0.21) and BD (P= 0.53). These results do not support that genetic variation in CSNK1D and CSNK1E is a susceptibility factor for major psychiatric disorders in the Japanese population. © 2012 Elsevier Ireland Ltd.

DOI： 10.1016/j.neulet.2012.08.070

Web of Science

Scopus

PubMed

researchmap

What is a rational antidepressant treatment for major depression in patients with Parkinson's disease? 査読有り

Hagikura, M; Iwamoto, K; Aleksic, B; Ozaki, N

PSYCHIATRY AND CLINICAL NEUROSCIENCES   66 巻 ( 5 ) 頁： 463 - 463   2012年8月

　詳細を見る

記述言語：英語   出版者・発行元：Psychiatry and Clinical Neurosciences  

DOI： 10.1111/j.1440-1819.2012.02362.x

Web of Science

Scopus

PubMed

researchmap

The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: The first case-control study in Asia 査読有り

Uno, Y; Uchiyama, T; Kurosawa, M; Aleksic, B; Ozaki, N

VACCINE   30 巻 ( 28 ) 頁： 4292 - 4298   2012年6月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Vaccine  

Objective: The aim of this study was to investigate the relationship between autism spectrum disorder (ASD) and general vaccinations, including measles-mumps-rubella (MMR) vaccine, in Japanese subjects, a population with high genetic homogeneity. Patients and methods: A case-control study was performed. Cases (n=189) were diagnosed with ASD, while controls (n=224) were volunteers from general schools, matched by sex and birth year to cases. Vaccination history and prenatal, perinatal, and neonatal factors from the Maternal and Child Health handbook, which was part of each subject's file, were examined. To determine the relationship between potential risk factors and ASD, crude odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated, and the differences in mean values of the quantitative variables between cases and controls were analyzed using an unpaired t-test. Moreover, MMR vaccination and the effect of the number of vaccine injections were investigated using a conditional multiple regression model. Results: For MMR vaccination, the OR was 1.04 (95% CI, 0.65-1.68), and no significant differences were found for the other vaccines. For all of the prenatal, perinatal and neonatal factors, there were no significant differences between cases and controls. Furthermore, regarding the presence of ASD, MMR vaccination and the number of vaccine injections had ORs of 1.10 (95% CI, 0.64-1.90) and 1.10 (95% CI, 0.95-1.26), respectively, in the conditional multiple regression model; no significant differences were found. Conclusions: In this study, there were not any convincing evidences that MMR vaccination and increasing the number of vaccine injections were associated with an increased risk of ASD in a genetically homogeneous population. Therefore, these findings indicate that there is no basis for avoiding vaccination out of concern for ASD. © 2012 Elsevier Ltd.

DOI： 10.1016/j.vaccine.2012.01.093

Web of Science

Scopus

PubMed

researchmap

No associations found between the genes situated at 6p22.1, HIST1H2BJ, PRSS16, and PGBD1 in Japanese patients diagnosed with schizophrenia 招待有り 査読有り

Kitazawa, M; Ohnuma, T; Takebayashi, Y; Shibata, N; Baba, H; Ohi, K; Yasuda, Y; Nakamura, Y; Aleksic, B; Yoshimi, A; Okochi, T; Ikeda, M; Naitoh, H; Hashimoto, R; Iwata, N; Ozaki, N; Takeda, M; Arai, H

AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS   159B 巻 ( 4 ) 頁： 456 - 464   2012年6月

　詳細を見る

記述言語：英語   出版者・発行元：American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics  

Recent GWAS demonstrated an association between candidate genes located at region 6p22.1 and schizophrenia. This region has been reported to house certain candidate SNPs, which may be associated with schizophrenia at HIST1H2BJ, PRSS16, and PGBD1. These genes may presumably be associated with pathophysiology in schizophrenia, namely epigenetics and psychoneuroimmunology. A three-step study was undertaken to focus on these genes with the following aims: (1) whether these genes may be associated in Japanese patients with schizophrenia by performing a 1st stage case-control study (514 cases and 706 controls) using Japanese tagging SNPs; (2) if the genetic regions of interest for the disease from the 1st stage of analyses were found, re-sequencing was performed to search for new mutations; (3) finally, a replication study was undertaken to confirm positive findings from the 1st stage were reconfirmed using a larger number of subjects (2,583 cases and 2,903 controls) during a 2nd stage multicenter replication study in Japan. Genotyping was performed using TaqMan PCR method for the selected nine tagging SNPs. Although three SNPs situated at the 3′ side of PGBD1; rs3800324, rs3800327, and rs2142730, and two-window haplotypes between rs3800327 and rs2142730 showed positive associations with schizophrenia, these associations did not have enough power to sustain significance during the 2nd stage replication study. In addition, re-sequencing for exons 5 and 6 situated at this region did not express any new mutations for schizophrenia. Taken together these results indicate that the genes HIST1H2BJ, PRSS16, and PGBD1 were not associated with Japanese patients with schizophrenia. © 2012 Wiley Periodicals, Inc.

DOI： 10.1002/ajmg.b.32049

Web of Science

Scopus

PubMed

researchmap

Slower adaptation to driving simulator and simulator sickness in older adults 査読有り

Kawano, N; Iwamoto, K; Ebe, K; Aleksic, B; Noda, A; Umegaki, H; Kuzuya, M; Iidaka, T; Ozaki, N

AGING CLINICAL AND EXPERIMENTAL RESEARCH   24 巻 ( 3 ) 頁： 285 - 289   2012年6月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Aging - Clinical and Experimental Research  

Background and aims: Methods of assessing driving abilities in the elderly are urgently needed. Although the driving simulator (DS) appears to be a safe and cost-effective method of objectively evaluating driving performance, it may pose adaptation problems for elderly adults. In this study, we examined age-related adaptation deficits on the DS. Methods: Healthy young adults (n=15) and healthy elderly persons (n=17) completed some neuropsychological tests, and then performed a road-tracking task with the DS, which was repeated four times (Trials 1-4). Results: After simulated driving in DS, simulator sickness (SS) was observed in 18.8% of participants. The frequency of SS was 29.4% in elderly adults and 6.7% in young adults, and 17.6% of the elderly participants dropped out of the experiment. Performance on the Necker cube copying task was significantly correlated with the onset of SS. Driving performance also showed a significant interaction between group and trial, for both driving accuracy and vehicle speed. In addition, the performance of elderly adults significantly improved between trials 1 and 4, reaching a plateau in trial 4, whereas that of young adults did not change across trials. Conclusion: This study provides preliminary evidence of slower adaptation to a DS-based driving task by older adults, which was associated with cognitive aging. Age affected driving accuracy and velocity when a road-tracking task was simply repeated. It is concluded that the capacity of elderly people to adapt to DS environments should be taken into consideration when evaluating their performance on DS tasks. ©2012, Editrice Kurtis.

DOI： 10.1007/BF03325260

Web of Science

Scopus

PubMed

researchmap

Common Variants in <i>MAGI2</i> Gene Are Associated with Increased Risk for Cognitive Impairment in Schizophrenic Patients 査読有り

Koide, T; Banno, M; Aleksic, B; Yamashita, S; Kikuchi, T; Kohmura, K; Adachi, Y; Kawano, N; Kushima, I; Nakamura, Y; Okada, T; Ikeda, M; Ohi, K; Yasuda, Y; Hashimoto, R; Inada, T; Ujike, H; Iidaka, T; Suzuki, M; Takeda, M; Iwata, N; Ozaki, N

PLOS ONE   7 巻 ( 5 ) 頁： e36836   2012年5月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：PLoS ONE  

Schizophrenia is a complex psychiatric disorder characterized by positive symptoms, negative symptoms, and cognitive impairment. MAGI2, a relatively large gene (~1.5 Mbps) that maps to chromosome 7q21, is involved in recruitment of neurotransmitter receptors such as AMPA- and NMDA-type glutamate receptors. A genetic association study designed to evaluate the association between MAGI2 and cognitive performance or schizophrenia has not been conducted. In this case-control study, we examined the relationship of single nucleotide polymorphism (SNP) variations in MAGI2 and risk for schizophrenia in a large Japanese sample and explored the potential relationships between variations in MAGI2 and aspects of human cognitive function related to glutamate activity. Based on the result of first schizophrenia genome-wide association study in a Japanese population (JGWAS), we selected four independent SNPs and performed an association study using a large independent Japanese sample set (cases 1624, controls 1621). Wisconsin Card Sorting Test (WCST) was used to evaluate executive function in 114 cases and 91 controls. We found suggestive evidence for genetic association of common SNPs within MAGI2 locus and schizophrenia in Japanese population. Furthermore in terms of association between MAGI2 and cognitive performance, we observed that genotype effect of rs2190665 on WCST score was significant (p = 0.034) and rs4729938 trended toward significance (p = 0.08). In conclusion, although we could not detect strong genetic evidence for association of common variants in MAGI2 and increased schizophrenia risk in a Japanese population, these SNPs may increase risk of cognitive impairment in schizophrenic patients. © 2012 Koide et al.

DOI： 10.1371/journal.pone.0036836

Web of Science

Scopus

PubMed

researchmap

Resequencing and Association Analysis of the <i>KALRN</i> and <i>EPHB1</i> Genes And Their Contribution to Schizophrenia Susceptibility 査読有り

Kushima, I; Nakamura, Y; Aleksic, B; Ikeda, M; Ito, Y; Shiino, T; Okochi, T; Fukuo, Y; Ujike, H; Suzuki, M; Inada, T; Hashimoto, R; Takeda, M; Kaibuchi, K; Iwata, N; Ozaki, N

SCHIZOPHRENIA BULLETIN   38 巻 ( 3 ) 頁： 552 - 560   2012年5月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Schizophrenia Bulletin  

Background: Our genome-wide association study of schizophrenia found association signals at the Kalirin gene (KALRN) and EPH receptor B1 gene (EPHB1) in a Japanese population. The importance of these synaptogenic pathway genes in schizophrenia is gaining independent supports. Although there has been growing interest in rare (<1%) missense mutations as potential contributors to the unexplained heritability of schizophrenia, there are no population-based studies targeting rare (<1%) coding mutations with a larger effect size (eg, OR >1.5) in KALRN or EPHB1.Methods and Results:The present study design consisted of 3 phases. At the discovery phase, we conducted resequencing analyses for all exon regions of KALRN and EPHB1 using a DNA microarray-based method. Seventeen rare (<1%) missense mutations were discovered in the first sample set (320 schizophrenic patients). After the prioritization phase based on frequencies in the second sample set (729 cases and 562 controls), we performed association analyses for each selected mutation using the third sample set (1511 cases and 1517 controls), along with a combined association analysis across all selected mutations. In KALRN, we detected a significant association between schizophrenia and P2255T (OR = 2.09, corrected P =. 048, 1 tailed); this was supported in the combined association analysis (OR = 2.07, corrected P =. 006, 1 tailed). We found no evidence of association of EPHB1 with schizophrenia. In silico analysis indicated the functional relevance of these rare missense mutations.Conclusion:We provide evidence that multiple rare (<1%) missense mutations in KALRN may be genetic risk factors for schizophrenia. © 2010 The Author.

DOI： 10.1093/schbul/sbq118

Web of Science

Scopus

PubMed

researchmap

Differential effects of diazepam, tandospirone, and paroxetine on plasma brain-derived neurotrophic factor level under mental stress

Tamaji, A; Iwamoto, K; Kawamura, Y; Takahashi, M; Ebe, K; Kawano, N; Kunimoto, S; Aleksic, B; Noda, Y; Ozaki, N

HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL   27 巻 ( 3 ) 頁： 329 - 333   2012年5月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：Wiley  

<jats:sec><jats:title>Objectives</jats:title><jats:p>Serum brain‐derived neurotrophic factor (BDNF) levels are reduced in depressed patients, and successful antidepressant treatment leads to increases in BDNF levels. However, little is known about how psychotropic drugs affect the mechanism of the human response to mental stress. We investigated the influence of psychotropic drugs on plasma BDNF levels under mental stress using a driving simulator (DS) task.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Fourteen healthy male volunteers received one of four drugs, diazepam (5 mg), tandospirone (20 mg), paroxetine (10 mg), and matched placebo, in a double‐blind, crossover manner. Subjects were asked to perform the DS task 4 h post‐dosing. Plasma BDNF levels were measured before and after the DS task.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Plasma BDNF levels under the placebo, diazepam, and tandospirone conditions significantly decreased after the DS task compared with before the task. Conversely, no significant differences in plasma BDNF levels were detected under the paroxetine condition.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>As these three psychotropic drugs have differential effects on plasma BDNF levels under mental stress after 4 h post‐dosing, antidepressants, unlike anxiolytics, might have a prompt positive effect on the mental stress response. Copyright © 2012 John Wiley & Sons, Ltd.</jats:p></jats:sec>

DOI： 10.1002/hup.2220

Web of Science

Scopus

PubMed

CiNii Research

researchmap

Sexual dysfunction and hyperprolactinemia in Japanese schizophrenic patients taking antipsychotics 査読有り

Kikuchi, T; Iwamoto, K; Sasada, K; Aleksic, B; Yoshida, K; Ozaki, N

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY   37 巻 ( 1 ) 頁： 26 - 32   2012年4月

　詳細を見る

記述言語：英語   出版者・発行元：Progress in Neuro-Psychopharmacology and Biological Psychiatry  

This study aimed to estimate the prevalence of sexual dysfunction, evaluated by the Nagoya Sexual Function Questionnaire (NSFQ), and hyperprolactinemia in patients with schizophrenia and examine a relationship between sexual dysfunction and serum prolactin levels. This cross-sectional, comparative study was performed using a sample comprising 195 Japanese schizophrenic in- and outpatients treated with antipsychotics (117 males and 78 females). Data were collected from October 2009 to January 2010 using single, cross-sectional ratings of sexual function assessed by the NSFQ and concurrent measurement of serum prolactin levels. The prevalence of sexual dysfunction in patients with schizophrenia was high (males 66.7%; females 79.5%). Hyperprolactinemia (> 25. ng/ml) was highly prevalent among schizophrenia patients, affecting 53.8% of females and 51.3% of males. Among female patients, 16.7% had prolactin levels > 100. ng/ml. There was no relationship between sexual dysfunction and serum prolactin levels. The present study demonstrated a higher prevalence of sexual dysfunction and hyperprolactinemia in Japanese schizophrenia patients. Clinicians should keep these problems in mind and discuss potential solutions with patients to improve patients' quality of life and adherence to therapy. © 2011 Elsevier Inc.

DOI： 10.1016/j.pnpbp.2011.11.016

Web of Science

Scopus

PubMed

researchmap

Prospective Study on the Association between Harm Avoidance and Postpartum Depressive State in a Maternal Cohort of Japanese Women 査読有り

Furumura, K; Koide, T; Okada, T; Murase, S; Aleksic, B; Hayakawa, N; Shiino, T; Nakamura, Y; Tamaji, A; Ishikawa, N; Ohoka, H; Usui, H; Banno, N; Morita, T; Goto, S; Kanai, A; Masuda, T; Ozaki, N

PLOS ONE   7 巻 ( 4 ) 頁： e34725   2012年4月

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：PLoS ONE  

Background: Recent studies have displayed increased interest in examining the relationship between personality traits and the onset, treatment response patterns, and relapse of depression. This study aimed to examine whether or not harm avoidance (HA) was a risk factor for postpartum depression measured by the Edinburgh Postnatal Depression Scale (EPDS) and the state dependency of HA. Methods: Pregnant women (n=460; mean age 31.9±4.2 years) who participated in a prenatal program completed the EPDS as a measure of depressive state and the Temperament and Character Inventory (TCI) as a measure of HA during three periods: early pregnancy (T1), late pregnancy (around 36 weeks), and 1 month postpartum (T2). Changes in EPDS and HA scores from T1 to T2 were compared between the non depressive (ND) group and the postpartum depressive (PD) group. Results: There was no significant difference in the level of HA between the ND and PD groups at T1. In the ND group, EPDS and HA scores did not change significantly from T1 to T2. In the PD group, both scores increased significantly from T1 to T2 (EPDS, p<0.0001; HA, p<0.048). In the ND and PD groups, a significant positive correlation was observed in changes in EPDS and HA scores from T1 to T2 (r=0.31, p=0.002). Conclusions: These results suggest that HA cannot be considered a risk factor for the development of postpartum depression measured by EPDS. Furthermore, HA may be state dependent. © 2012 Furumura et al.

DOI： 10.1371/journal.pone.0034725

Web of Science

Scopus

PubMed

researchmap

Combination use of Beck Depression Inventory and two-question case-finding instrument as a screening tool for depression in the workplace 査読有り

Adachi, Y; Aleksic, B; Nobata, R; Suzuki, T; Yoshida, K; Ono, Y; Ozaki, N

BMJ OPEN   2 巻 ( 3 )   2012年

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：BMJ Open  

Objectives: The present study aimed to validate screening tools that could be used to identify depression among workers. Design: Diagnostic test study. Settings: Workers from three Japanese companies agreed to participate. Participants: Recruitment for the group 1 occurred between January 2001 and February 2004, and 89 participants (81 men and 8 women with a mean age of 38.4±6.6 years) (98.8%) took part in the study. Recruitment for the group 2 occurred between July 2000 and February 2004, and 1500 participants (1408 men and 92 women with a mean age of 40.9±7.2 years) (94.2%) took part in the study. Demographic data are shown in supplementary table 1. Interventions: Primary and secondary outcome measures: the Beck Depression Inventory (BDI) and a two-question case-finding instrument (TQI) were administered to 89 workers and Mini-International Neuropsychiatric Interview was conducted to verify the diagnosis of depression. A second group of 1500 workers completed the BDI and TQI to detect possible sample bias for the distribution of depression. Specificity, sensitivity and positive predictive value were calculated in order to obtain the optimal cut-off scores for BDI and TQI and receiver operating characteristic curves, and Youden Index were applied to further refine the optimal cut-off scores. Results: When paired together, BDI score ≥10 and TQI score of 2 adequately identified workers who had major depressive disorder and those who had other psychiatric disorders that are frequently comorbid with major depressive disorder. Conclusions: The combination of BDI score &ge10 and TQI score of 2 can adequately screen for current and potential cases of depression among workers. Furthermore, BDI and TQI offer the advantage of being relatively easy to administer to a large number of workers. Early detection of depression could improve treatment outcomes and decrease economic burden. Trail registration:.

DOI： 10.1136/bmjopen-2011-000596

Web of Science

Scopus

PubMed

researchmap

Wisconsin Card Sorting Test scores and clinical and sociodemographic correlates in Schizophrenia: multiple logistic regression analysis 査読有り

Banno, M; Koide, T; Aleksic, B; Okada, T; Kikuchi, T; Kohmura, K; Adachi, Y; Kawano, N; Iidaka, T; Ozaki, N

BMJ OPEN   2 巻 ( 6 )   2012年

　詳細を見る

記述言語：英語   掲載種別：研究論文（学術雑誌）   出版者・発行元：BMJ Open  

Objectives: This study investigated what clinical and sociodemographic factors affected Wisconsin Card Sorting Test (WCST) factor scores of patients with schizophrenia to evaluate parameters or items of the WCST. Design: Cross-sectional study. Setting: Patients with schizophrenia from three hospitals participated. Participants: Participants were recruited from July 2009 to August 2011. 131 Japanese patients with schizophrenia (84 men and 47 women, 43.5±13.8 years (mean±SD)) entered and completed the study. Participants were recruited in the study if they (1) met DSM-IV criteria for schizophrenia; (2) were physically healthy and (3) had no mood disorders, substance abuse, neurodevelopmental disorders, epilepsy or mental retardation. We examined their basic clinical and sociodemographic factors (sex, age, education years, age of onset, duration of illness, chlorpromazine equivalent doses and the positive and negative syndrome scale (PANSS) scores). Primary and secondary outcome measures: All patients carried out the WCST Keio version. Five indicators were calculated, including categories achieved (CA), perseverative errors in Milner (PEM) and Nelson (PEN), total errors (TE) and difficulties of maintaining set (DMS). From the principal component analysis, we identified two factors (1 and 2). We assessed the relationship between these factor scores and clinical and sociodemographic factors, using multiple logistic regression analysis. Results: Factor 1 was mainly composed of CA, PEM, PEN and TE. Factor 2 was mainly composed of DMS. The factor 1 score was affected by age, education years and the PANSS negative scale score. The factor 2 score was affected by duration of illness. Conclusions: Age, education years, PANSS negative scale score and duration of illness affected WCST factor scores in patients with schizophrenia. Using WCST factor scores may reduce the possibility of type I errors due to multiple comparisons.

DOI： 10.1136/bmjopen-2012-001340

Web of Science

Scopus

PubMed

researchmap

Evaluation of Factors Affecting Continuous Performance Test Identical Pairs Version Score of Schizophrenic Patients in a Japanese Clinical Sample

Takayoshi Koide, Branko Aleksic, Tsutomu Kikuchi, Masahiro Banno, Kunihiro Kohmura, Yasunori Adachi, Naoko Kawano, Tetsuya Iidaka, Norio Ozaki

Schizophrenia Research and Treatment   2012 巻   頁： 1 - 5   2012年

　詳細を見る

記述言語：英語   出版者・発行元：Hindawi Limited  

<jats:p><jats:italic>Aim</jats:italic>. Cognitive impairment in schizophrenia strongly relates to social outcome and is a good candidate for endophenotypes. When we accurately measure drug efficacy or effects of genes or variants relevant to schizophrenia on cognitive impairment, clinical factors that can affect scores on cognitive tests, such as age and severity of symptoms, should be considered. To elucidate the effect of clinical factors, we conducted multiple regression analysis using scores of the Continuous Performance Test Identical Pairs Version (CPT-IP), which is often used to measure attention/vigilance in schizophrenia.<jats:italic>Methods</jats:italic>. We conducted the CPT-IP (4-4 digit) and examined clinical information (sex, age, education years, onset age, duration of illness, chlorpromazine-equivalent dose, and Positive and Negative Symptom Scale (PANSS) scores) in 126 schizophrenia patients in Japanese population. Multiple regression analysis was used to evaluate the effect of clinical factors.<jats:italic>Results</jats:italic>. Age, chlorpromazine-equivalent dose, and PANSS-negative symptom score were associated with mean d<jats:sup>′</jats:sup>score in patients. These three clinical factors explained about 28% of the variance in mean d<jats:sup>′</jats:sup>score.<jats:italic>Conclusions</jats:italic>. As conclusion, CPT-IP score in schizophrenia patients is influenced by age, chlorpromazine-equivalent dose and PANSS negative symptom score.</jats:p>

DOI： 10.1155/2012/970131

PubMed

CiNii Research

researchmap